MED19 and breast cancer: Interestingly, LCMR1 (MED19) reportedly down-regulates C-X-C motif chemokine ligand 11 (CXCL11) in breast cancer; blocking LCMR1 contributes to high CXCL11 levels and positively correlates with antitumor immune responses [40].